Obesity, polycystic ovary syndrome and anovulation - How are they interrelated?

Current Opinion in Obstetrics and Gynecology

Volumn 13, Issue 3, 2001, Pages 323-327

  Norman, Robert J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; METFORMIN; TROGLITAZONE;

ANOVULATION; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANOVULATION; FEMALE; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 0034913125     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200106000-00013     Document Type: Review

References (28)

1. The importance of diagnosing the polycystic ovary syndrome
2. Polycystic ovary syndrome
3. Sonographic parameters and hormonal status in lean and obese women with polycystic ovary syndrome
4. The genetics of obesity. Lessons for polycystic ovary syndrome
5. Allelic variants of the follistatin gene in polycystic ovary syndrome
6. Preliminary investigation of follistatin gene mutations in women with polycystic ovary syndrome
7. No association between body mass index and beta(3)-adrenergic receptor variant (W64R) in children with premature pubarche and adolescent girls with hyperandrogenism
8. Searching for the polycystic ovary syndrome genes
9. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries
10. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain
11. Hypothalamic-pituitary-adrenal axis sensitivity to opioids in women with polycystic ovary syndrome
12. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: Effects of being overweight and relevance to hyperandrogenism
13. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity
14. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome
15. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus
16. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study
17. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome
18. Influence of insulin resistance on total renin level in normotensive women with polycystic ovary syndrome
19. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)
20. Internal carotid artery haemodynamics in women with polycystic ovaries
21. Obesity and reproductive disorders: A review
22. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment
23. Obesity, insulin, sex steroids and ovulation
24. Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome
25. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study
26. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
27. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome
28. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage